{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+C&page=11",
    "query": {
      "intervention": "Dose C",
      "page": 11
    },
    "page_size": 10
  },
  "pagination": {
    "page": 11,
    "page_size": 10,
    "total_count": 3877,
    "total_pages": 388,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+C&page=12&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+C&page=10&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-19T22:32:53.664Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02096263",
      "title": "Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Poliomyelitis",
        "Diphtheria",
        "Haemophilus Influenzae Type b",
        "Tetanus",
        "Acellular Pertussis",
        "Hepatitis B"
      ],
      "interventions": [
        {
          "name": "Infanrix hexa",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pediarix",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ActHIB",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pentacel",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Engerix-B",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Infanrix",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Hiberix",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Prevnar13",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Rotarix",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Weeks",
        "maximum_age": "12 Weeks",
        "sex": "ALL",
        "summary": "6 Weeks to 12 Weeks"
      },
      "enrollment_count": 585,
      "start_date": "2014-04-16",
      "completion_date": "2015-11-13",
      "has_results": true,
      "last_update_posted_date": "2019-11-27",
      "last_synced_at": "2026-10-19T22:32:53.664Z",
      "location_count": 43,
      "location_summary": "Tucson, Arizona • Fayetteville, Arkansas • Anaheim, California + 38 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Daly City",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02096263"
    },
    {
      "nct_id": "NCT01322321",
      "title": "ACZ885 in Type 1 Diabetes Mellitus",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetes Mellitus",
        "Diabetes Type 1"
      ],
      "interventions": [
        {
          "name": "ACZ885",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "6 Years to 35 Years"
      },
      "enrollment_count": 0,
      "start_date": "2011-03",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2012-09-05",
      "last_synced_at": "2026-10-19T22:32:53.664Z",
      "location_count": 1,
      "location_summary": "Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01322321"
    },
    {
      "nct_id": "NCT02324049",
      "title": "Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 in Mucopolysaccharidosis III, Type B (MPS IIIB)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Mucopolysaccharidosis IIIB"
      ],
      "interventions": [
        {
          "name": "SBC-103",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "2 Years to 12 Years"
      },
      "enrollment_count": 11,
      "start_date": "2015-01-22",
      "completion_date": "2017-10-16",
      "has_results": true,
      "last_update_posted_date": "2018-08-21",
      "last_synced_at": "2026-10-19T22:32:53.664Z",
      "location_count": 2,
      "location_summary": "Minneapolis, Minnesota • Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02324049"
    },
    {
      "nct_id": "NCT01527149",
      "title": "Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stage I Mantle Cell Lymphoma",
        "Stage II Contiguous Mantle Cell Lymphoma",
        "Stage II Non-Contiguous Mantle Cell Lymphoma",
        "Stage III Mantle Cell Lymphoma",
        "Stage IV Mantle Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Autologous Hematopoietic Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Ofatumumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Vincristine Sulfate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 37,
      "start_date": "2011-12-06",
      "completion_date": "2024-01-11",
      "has_results": true,
      "last_update_posted_date": "2024-02-07",
      "last_synced_at": "2026-10-19T22:32:53.664Z",
      "location_count": 2,
      "location_summary": "Buffalo, New York • Nashville, Tennessee",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01527149"
    },
    {
      "nct_id": "NCT00369317",
      "title": "Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Childhood Acute Basophilic Leukemia",
        "Childhood Acute Eosinophilic Leukemia",
        "Childhood Acute Erythroleukemia (M6)",
        "Childhood Acute Megakaryocytic Leukemia (M7)",
        "Childhood Acute Minimally Differentiated Myeloid Leukemia (M0)",
        "Childhood Acute Monoblastic Leukemia (M5a)",
        "Childhood Acute Monocytic Leukemia (M5b)",
        "Childhood Acute Myeloblastic Leukemia With Maturation (M2)",
        "Childhood Acute Myeloblastic Leukemia Without Maturation (M1)",
        "Childhood Acute Myelomonocytic Leukemia (M4)",
        "Childhood Myelodysplastic Syndromes",
        "de Novo Myelodysplastic Syndromes",
        "Secondary Acute Myeloid Leukemia",
        "Secondary Myelodysplastic Syndromes",
        "Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies"
      ],
      "interventions": [
        {
          "name": "asparaginase",
          "type": "DRUG"
        },
        {
          "name": "daunorubicin hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "cytarabine",
          "type": "DRUG"
        },
        {
          "name": "thioguanine",
          "type": "DRUG"
        },
        {
          "name": "etoposide",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Children's Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "4 Years",
        "sex": "ALL",
        "summary": "Up to 4 Years"
      },
      "enrollment_count": 205,
      "start_date": "2007-03",
      "completion_date": "2021-12-31",
      "has_results": true,
      "last_update_posted_date": "2022-01-28",
      "last_synced_at": "2026-10-19T22:32:53.664Z",
      "location_count": 88,
      "location_summary": "Phoenix, Arizona • Downey, California • Long Beach, California + 73 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Downey",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Madera",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00369317"
    },
    {
      "nct_id": "NCT00411385",
      "title": "Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared to Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients Geno2/3",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Hepatitis C"
      ],
      "interventions": [
        {
          "name": "albumin interferon alfa-2b",
          "type": "DRUG"
        },
        {
          "name": "peginterferon alfa-2a",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Human Genome Sciences Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 933,
      "start_date": "2007-02",
      "completion_date": "2008-10",
      "has_results": false,
      "last_update_posted_date": "2013-08-08",
      "last_synced_at": "2026-10-19T22:32:53.664Z",
      "location_count": 28,
      "location_summary": "Phoenix, Arizona • La Jolla, California • San Francisco, California + 20 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00411385"
    },
    {
      "nct_id": "NCT02850406",
      "title": "Study to Evaluate the Effect of GBT440 in Pediatrics With Sickle Cell Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sickle Cell Disease"
      ],
      "interventions": [
        {
          "name": "Voxelotor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Months to 17 Years"
      },
      "enrollment_count": 147,
      "start_date": "2016-07-05",
      "completion_date": "2023-10-02",
      "has_results": true,
      "last_update_posted_date": "2025-08-15",
      "last_synced_at": "2026-10-19T22:32:53.664Z",
      "location_count": 13,
      "location_summary": "Brentwood, California • Washington D.C., District of Columbia • Atlanta, Georgia + 9 more",
      "locations": [
        {
          "city": "Brentwood",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02850406"
    },
    {
      "nct_id": "NCT04501276",
      "title": "A Phase 1b/2 Study of ADG116, ADG116 Combined With Anti-PD-1 Antibody or Anti-CD137 Antibody in Solid Tumors Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced/Metastatic Solid Tumors"
      ],
      "interventions": [
        {
          "name": "ADG116",
          "type": "DRUG"
        },
        {
          "name": "ADG106",
          "type": "DRUG"
        },
        {
          "name": "anti PD1 drug",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Adagene Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 72,
      "start_date": "2020-09-23",
      "completion_date": "2025-11-30",
      "has_results": false,
      "last_update_posted_date": "2026-01-08",
      "last_synced_at": "2026-10-19T22:32:53.664Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04501276"
    },
    {
      "nct_id": "NCT03536754",
      "title": "A Study of CCX140-B in Subjects With FSGS",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "FSGS",
        "Focal Segmental Glomerulosclerosis",
        "Glomerulosclerosis"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "CCX140-B",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 46,
      "start_date": "2018-05-17",
      "completion_date": "2020-02-19",
      "has_results": true,
      "last_update_posted_date": "2025-03-13",
      "last_synced_at": "2026-10-19T22:32:53.664Z",
      "location_count": 9,
      "location_summary": "Phoenix, Arizona • Torrance, California • Shreveport, Louisiana + 6 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Shreveport",
          "state": "Louisiana"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03536754"
    },
    {
      "nct_id": "NCT05007782",
      "title": "Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "interventions": [
        {
          "name": "Denikitug",
          "type": "DRUG"
        },
        {
          "name": "Zimberelimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 304,
      "start_date": "2021-08-18",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2026-09-17",
      "last_synced_at": "2026-10-19T22:32:53.664Z",
      "location_count": 10,
      "location_summary": "La Jolla, California • Palo Alto, California • New Haven, Connecticut + 6 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05007782"
    }
  ]
}